Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LIVERAIM

Financiado

Cerrado

A Biomarker Based Platform for Early Diagnosis of Chronic Liver Disease to Enabl...

A Biomarker Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, causing 300K deaths per year in Europe. Predominant etiological factors are obesity, typ... ver más

28/02/2030

FUNDACIO CLINIC PE...

25M€

Presupuesto del proyecto: 25M€

Líder del proyecto

FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 650K€

Fecha límite participación Sin fecha límite de participación.

Ver 32 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-27

HORIZON-JU-IHI-2022-03-01: Screening platform and biomarkers f... ExpectedOutcome:R&I actions (projects) to be supported under this topic should aim to deliver re...

I+D

Cerrada hace 1 año

0% 56% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

32 Participantes

FUNDACIO CLINIC PER A LA REC...

3.14M€ | Lider

BII GMBH

350.00K€ | Participante

471.04K€ | Participante

UZH

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

HEPCIR Cell circuits as targets and biomarkers for liver disease an... 2M€ Cerrado

LiverPRO Timely detection of a potentially fatal chronic liver diseas... 75K€ Cerrado

halt-RONIN Discovering chronic inflammation biomarkers that define key... 7M€ Cerrado

IT-LIVER STRATEGY TO INHIBIT TGF Beta IN LIVER DISEASE 3M€ Cerrado

LiverScreen Screening for liver fibrosis population based study across... 6M€ Cerrado

RENAISSANCE Advanced biomarker discovery for earlier diagnosis and impro... 150K€ Cerrado

Duración del proyecto: 75 meses Fecha Inicio: 2023-11-27
Fecha Fin: 2030-02-28

Líder del proyecto

FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 650K€

Presupuesto del proyecto 25M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, causing 300K deaths per year in Europe. Predominant etiological factors are obesity, type2 diabetes, and increased alcohol in-take, which are all on the rise. It is predicted that healthy life expectancy will decrease in Europe over the next 30 years because of deaths due to liver disease. Liver cirrhosis develops after a very long period of asymptomatic liver fibrosis, staying undetected until patients develop severe complications due to cirrhosis or liver cancer. Currently the only effective treatment available is liver transplantation which is not applicable to all patients. If fibrosis is detected early, to target the course of liver disease, then liver fibrosis is reversible. The LIVERAIM project concentrates a team of renowned clinical centres and Industrial partners, including SMEs, with great expertise in the field of Liver Disease, the aim being to design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions. A large number of existing biomarkers will be tested for fibrosis prediction accuracy using biobank plasma samples from 40,000 subjects from previous H2020 EU-funded cohorts. LIVERAIM will develop a screening platform with biomarkers using AI for personalized early diagnosis of fibrosis to be validated in a RCT of 100K subjects from 6 representative EU countries. The platform will be linked to tailored, personalized therapeutic interventions to halt fibrosis progression. With LIVERAIM, early diagnosis and personalized intervention can stop liver disease progression, help decrease morbidity and mortality and the associated societal burdens both economic and health inequity.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores